
NPS Benzodiazepines in the United States

03 2023

PURPOSE: This report provides up-to-date information regarding the status of NPS benzodiazepine prevalence and positivity in the United States.

OVERVIEW: Novel psychoactive substances (NPS), including NPS benzodiazepines, continue to pose great challenges for forensic scientists, clinicians, and public health and safety personnel. NPS benzodiazepines have been implicated in an increasing number of adverse health events, marked by emergency room admissions and death investigations, especially when ingested in combination with opioids. Maintaining a current scope of analysis can be challenging, requiring comprehensive analytical methodologies and reference materials for identification(s).


OBJECTIVE: Our laboratory utilizes novel approaches for the analysis of drugs in biological samples and seized materials using comprehensive nontargeted data acquisition by gas chromatography mass spectrometry (GC-MS) and liquid chromatography quadrupole time-of-flight mass spectrometry (LC-QTOF-MS). The scope of analysis contains more than 1,100 drugs, including a vast majority of NPS and their metabolites. This approach allows for real-time identification of new benzodiazepines and further data analysis of important trends. This project was conducted in collaboration with the toxicology and criminalistics laboratories of NMS Labs. Forensic case types linked to these results include illicit drug investigations, medicolegal death investigations, and/or driving under the influence of drugs (DUID) investigations. The results in this report represent the total number of NPS identifications at the CFSRE during this guarter, including those from sample-mining, data-mining, and/or esoteric testing.



NPS BENZODIAZEPINES IDENTIFIED

Flubromazolam	1	ΓοχίςοΙος	gy <mark>=</mark> Dr	ug Mater	ial	
Desalkylflurazepam	3					50
Pyrazolam	4					45 40
Etizolam	9					35
Desalkylgidazepam	11					30 25
Flualprazolam	12					20
Flubromazepam	17					15 10
Bromazolam					349	5
	0 -	100	200	300		0

SELECT POSITIVITY: Q4 2020 to Q3 2023



cfsre **ONPS** DISCOVERY

Walton, MS; Amanda LA, Mohr, MSFS, D-ABFT-FT; and Barry K, Logan, PhD, F-ABFT at the NMS Labs for their involvements and contributions. For more information about our our website at www.npsdiscovery.org

ACKNOWLEDGEMENTS: This report was prepared by Alex J. Krotulski, PhD; Sara E. FUNDING: CFSRE's NPS Discovery is supported by the National Institute of Justice, Office of Justice Programs, U.S. Department of Justice (Award Number 15PNIJ-22-GG-04434-Center for Forensic Science Research and Education (CFSRE) at the Fredric Rieders Family MUMU, "Implementation of NPS Discovery - An Early Warning System for Novel Drug Foundation. CFSRE's NPS Discovery program acknowledges scientists at the CFSRE and Intelligence, Surveillance, Monitoring, Response, and Forecasting using Drug Materials and Toxicology Populations in the US"). The opinions, findings, conclusions and/or programs and reports, please contact NPS Discovery at npsdiscovery@cfsre.org or visit recommendations expressed in this publication are those of the author(s) and do not necessarily represent the official position or policies of the U.S. Department of Justice